Interaction Checker

Sorafenib etkileşimleri

Sorafenib (Nexavar) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 210 belgelenmiş etkileşim var: 38 majör, 172 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (38)

  • AksitinibMajör

    Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see Adverse Reactions (6.1) ] . (Aksitinib etiketi, Uyarılar ve önlemler)

  • AprepitantCYP3A4 inhibitörüMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • BosentanCYP3A4 indükleyicisiMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • Deferasiroksdemir takviyesiMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • GemsitabinantimetabolitMajör

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • GriseofulvinantifungalMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • KarboplatinMajör

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (Sorafenib etiketi, Kontrendikasyonlar)

  • KlobazambenzodiazepinMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • LorlatinibCYP3A4 indükleyicisiMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • MitapivatCYP3A4 indükleyicisiMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • NeomisinaminoglikozidMajör

    Avoid concomitant use of NEXAVAR with neomycin. (Sorafenib etiketi, İlaç etkileşimleri)

  • NevirapinantiretroviralMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • PaklitakselMajör

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (Sorafenib etiketi, Kontrendikasyonlar)

  • PrimidonantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • RifabutinantibiyotikMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • SisplatinMajör

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • SuzetrijinCYP3A4 indükleyicisiMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanMajör

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (Sorafenib etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (172)

  • AdenozinantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Alfuzosinalfa blokerOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • AliskirenantihipertansifOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amiloridpotasyum tutucu diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • AmiodaronantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amitriptilintrisiklik antidepresanOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amlodipindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • AnagrelidQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Arsenik trioksitQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Asebutololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • AsenapinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Atenololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Atenolol ve klortalidonbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Azitromisinmakrolid antibiyotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • BenazeprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Benazepril ve hidroklorotiyazidACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Betaksololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Bisoprololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Bisoprolol ve hidroklorotiyazidbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Dekstrometorfan ve kinidinserotonerjik ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Digoksindijital glikozidiOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Diltiazemkalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • DisopiramidantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • DofetilidantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Doksazosinalfa blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • DötetrabenazinVMAT2 inhibitörüOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • DronedaronantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Droperidoldopamin antagonistiOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • EnalaprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • EnalaprilatACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Eplerenonaldosteron antagonistiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Eritromisinmakrolid antibiyotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Esmololbeta blokerOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • EssitalopramSSRIOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Etakrinik asitkıvrım (loop) diüretiğiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Felodipindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Fenoksibenzaminalfa blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • FingolimodimmünosüpresanOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • FlekainidantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Flukonazolazol antifungalOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • FluoksetinSSRIOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • FosinoprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Fosinopril ve hidroklorotiyazidACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • GranisetronQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Guanfasinalfa adrenerjik agonistOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • HaloperidolantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • HidralazinvazodilatörOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Hidroklorotiyazidtiyazid diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • HidroksiklorokinQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • HidroksizinantihistaminikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İbutilidantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İloperidonantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İndapamidtiyazid diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İsradipindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • İzosorbid dinitrat ve hidralazinnitratOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KaptoprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Karvedilolbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KetiapinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Ketokonazolazol antifungalOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KinaprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KinidinantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KininantimalaryalOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Klaritromisinmakrolid antibiyotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Klonidinalfa adrenerjik agonistOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KlorokinantimalaryalOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Klorotiyazidtiyazid diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KlorpromazinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Klortalidontiyazid diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • KlozapinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Labetalolbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • LevofloksasinflorokinolonOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Levotiroksintiroid hormonuOrta

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Levotiroksin ve liyotironintiroid hormonuOrta

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Lidokainlokal anestezikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Lidokain ve prilokainlokal anestezikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • LisinoprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Lisinopril ve hidroklorotiyazidACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Liyotironintiroid hormonuOrta

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Lofeksidinalfa adrenerjik agonistOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • LoperamidQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Losartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MekamilaminantihipertansifOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MeksiletinantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MetadonopioidOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MetildopaantihipertansifOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Metimazolantitiroid ilaçOrta

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Metolazontiyazid diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Metoprololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Metoprolol ve hidroklorotiyazidbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MinoksidilvazodilatörOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MoeksiprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • MoksifloksasinflorokinolonOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Nadololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Nebivololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Nikardipindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • NilotinibQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • NitroprussidvazodilatörOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • OfloksasinflorokinolonOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Olanzapin ve fluoksetinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • OndansetronQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PaliperidonantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PentamidinQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PerindoprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PimavanserinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PimozidantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Pindololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PitolisantQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Posakonazolazol antifungalOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Prazosinalfa blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • ProkainamidantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PrometazinantihistaminikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Prometazin ve dekstrometorfanantihistaminikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Prometazin ve kodeinopioidOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • PropafenonantiaritmikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Propiltiourasilantitiroid ilaçOrta

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Propranololbeta blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • RamiprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • RanolazinQT aralığını uzatan ilaçOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • RisperidonantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • SiprofloksasinflorokinolonOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • SitalopramSSRIOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • SolifenasinantikolinerjikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Sotalolbeta blokerOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Spironolaktonaldosteron antagonistiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TakrolimusimmünosüpresanOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Tamoksifenselektif östrojen reseptör modülatörüOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Terazosinalfa blokerOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Teriparatidtiroid hormonuOrta

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TetrabenazinVMAT2 inhibitörüOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TioridazinantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Tizanidinkas gevşeticiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TolterodinantikolinerjikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Torasemidkıvrım (loop) diüretiğiOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Toremifenselektif östrojen reseptör modülatörüOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TramadolopioidOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Tramadol ve parasetamolopioidOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TrandolaprilACE inhibitörüOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • TrazodonantidepresanOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • ValbenazinVMAT2 inhibitörüOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • VardenafilPDE5 inhibitörüOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • VarfarinantikoagülanOrta

    Increased Risk of Bleeding with Concomitant Use of Warfarin Infrequent bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on NEXAVAR. (Sorafenib etiketi, Uyarılar ve önlemler)

  • VenlafaksinSNRIOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Verapamilkalsiyum kanal blokeriOrta

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Vorikonazolazol antifungalOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

  • ZiprasidonantipsikotikOrta

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

Kullandığınız her şeyi Sorafenib ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.